There is 1 paper on peripheral thrombocytopenia in aging research: 1 trial in people.
1 paper studies it1 finding
See all 1 papers on peripheral thrombocytopenia
- Human trial1
Interventions
1Navitoclax
upin humans1OR 4
1 study
Navitoclax
upin humans1OR 4
Navitoclax induces peripheral thrombocytopenia in humans (attributed to high-affinity BCL-XL inhibition) (grade 3 or 4 thrombocytopenia in 29 patients).
“Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”
Human trialattributed to high-affinity BCL-XL inhibition
The Lancet. Oncology
Latest
The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Non-randomized trial in 55 peopleNavitoclax